Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling

Journal of Biological Chemistry

Volumn 289, Issue 32, 2014, Pages 21960-21972

  Moreno, Estefanía ^a,b   Andradas, Clara ^c,d   Medrano, Mireia ^a,b   Caffarel, María M ^c   Pérez Gómez, Eduardo ^c,d   Blasco Benito, Sandra ^c,d   Gómez Cañas, María ^b,c,e   Pazos, M Ruth ^b,c   Irving, Andrew J ^f   Lluís, Carme ^a,b   Canela, Enric I ^a,b   Fernández Ruiz, Javier ^b,c,e   Guzmán, Manuel ^b,c,e   McCormick, Peter J ^a,b,g   Sánchez, Cristina ^c,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d Department of Biochemistry and Molecular Biology i School of Biology Complutense University ^*  (Spain)

^e INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; BIOLOGY;

BIPHASIC EFFECTS; CANCER CELLS; CANNABINOID RECEPTORS; CANNABINOIDS; CONTROL-CELL;

CELLS;

CANNABINOID; CANNABINOID 2 RECEPTOR; CNR2 PROTEIN, HUMAN; DRONABINOL; G PROTEIN COUPLED RECEPTOR; GPR55 PROTEIN, HUMAN; RECOMBINANT PROTEIN; SMALL INTERFERING RNA;

ANIMAL; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE TARGETING; GENETICS; GLIOBLASTOMA; HEK293 CELL LINE; HUMAN; MALE; METABOLISM; MOUSE; NEOPLASMS; NUDE MOUSE; PROTEIN QUATERNARY STRUCTURE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CANNABINOIDS; CELL LINE, TUMOR; DRONABINOL; FEMALE; GENE TARGETING; GLIOBLASTOMA; HEK293 CELLS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS; PROTEIN STRUCTURE, QUATERNARY; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905841270     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.561761     Document Type: Article

References (38)

1. Dorsam, R. T., and Gutkind, J. S. (2007) G-protein-coupled receptors and cancer. Nat. Rev. Cancer 7, 79-94
2. Rosenbaum, D. M., Rasmussen, S. G., and Kobilka, B. K. (2009) The structure and function of G-protein-coupled receptors. Nature 459, 356-363
3. Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., Mechoulam, R., and Ross, R. A. (2010) International Union of Basic and Clinical Pharmacology: LXXIX: cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol. Rev. 62, 588-631
4. Pacher, P., Bátkai, S., and Kunos, G. (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58, 389-462
5. Guzmán, M., Sánchez, C., and Galve-Roperh, I. (2002) Cannabinoids and cell fate. Pharmacol. Ther. 95, 175-184
6. Velasco, G., Sánchez, C., and Guzmán, M. (2012) Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 12, 436-444
7. Brown, A. J. (2007) Novel cannabinoid receptors. Br. J. Pharmacol. 152, 567-575
8. Ross, R. A. (2009) The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 30, 156-163
9. Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., and Sugiura, T. (2007) Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 362, 928-934
10. Pertwee, R. G. (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 17, 1360-1381
11. Henstridge, C. M., Balenga, N. A., Kargl, J., Andradas, C., Brown, A. J., Irving, A., Sanchez, C., and Waldhoer, M. (2011) Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol- sensitive receptor GPR55. Mol. Endocrinol. 25, 1835-1848
12. Andradas, C., Caffarel, M. M., Pérez-Gómez, E., Salazar, M., Lorente, M., Velasco, G., Guzmán, M., and Sánchez, C. (2011) The orphan G proteincoupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30, 245-252
13. Pérez-Gómez, E., Andradas, C., Flores, J. M., Quintanilla, M., Paramio, J. M., Guzmán, M., and Sánchez, C. (2013) The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene 32, 2534-2542
14. Piñeiro, R., Maffucci, T., and Falasca, M. (2011) The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30, 142-152
15. Rozenfeld, R., and Devi, L. A. (2010) Receptor heteromerization and drug discovery. Trends Pharmacol. Sci. 31, 124-130
16. Balenga, N. A., Aflaki, E., Kargl, J., Platzer, W., Schröder, R., Blättermann, S., Kostenis, E., Brown, A. J., Heinemann, A., and Waldhoer, M. (2011) GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res. 21, 1452-1469
17. Henstridge, C. M., Balenga, N. A., Ford, L. A., Ross, R. A., Waldhoer, M., and Irving, A. J. (2009) The GPR55 ligand L-lysophosphatidylinositol promotes RhoA-dependent Ca2 signaling and NFAT activation. FASEB J. 23, 183-193
18. González, S., Rangel-Barajas, C., Peper, M., Lorenzo, R., Moreno, E., Ciruela, F., Borycz, J., Ortiz, J., Lluís, C., Franco, R., McCormick, P. J., Volkow, N. D., Rubinstein, M., Floran, B., and Ferré, S. (2012) Dopamine D4 recep-tor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain. Mol. Psychiatry 17, 650-662
19. Callén, L., Moreno, E., Barroso-Chinea, P., Moreno-Delgado, D., Cortés, A., Mallol, J., Casadó, V., Lanciego, J. L., Franco, R., Lluis, C., Canela, E. I., and McCormick, P. J. (2012) Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J. Biol. Chem. 287, 20851-20865
20. Carriba, P., Navarro, G., Ciruela, F., Ferré, S., Casadó, V., Agnati, L., Cortés, A., Mallol, J., Fuxe, K., Canela, E. I., Lluís, C., and Franco, R. (2008) Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat. Methods 5, 727-733
21. Söderberg, O., Leuchowius, K. J., Gullberg, M., Jarvius, M., Weibrecht, I., Larsson, L. G., and Landegren, U. (2008) Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 45, 227-232
22. Trifilieff, P., Rives, M. L., Urizar, E., Piskorowski, R. A., Vishwasrao, H. D., Castrillon, J., Schmauss, C., Slättman, M., Gullberg, M., and Javitch, J. A. (2011) Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. BioTechniques 51, 111-118
23. Schröder, R., Janssen, N., Schmidt, J., Kebig, A., Merten, N., Hennen, S., Müller, A., Blättermann, S., Mohr-Andrä, M., Zahn, S., Wenzel, J., Smith, N. J., Gomeza, J., Drewke, C., Milligan, G., Mohr, K., and Kostenis, E. (2010) Deconvolution of complexGprotein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat. Biotechnol. 28, 943-949
24. Mato, S., Vidal, R., Castro, E., Díaz, A., Pazos, A., and Valdizán, E. M. (2010) Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine 1A receptor-dependent mechanisms. Mol. Pharmacol. 77, 424-434
25. Anavi-Goffer, S., Baillie, G., Irving, A. J., Gertsch, J., Greig, I. R., Pertwee, R. G., and Ross, R. A. (2012) Modulation of L-lysophosphatidylinositol/ GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J. Biol. Chem. 287, 91-104
26. Lorente, M., Torres, S., Salazar, M., Carracedo, A., Hernández- Tiedra, S., Rodríguez-Fornés, F., García-Taboada, E., Meléndez, B., Mollejo, M., Campos-Martín, Y., Lakatosh, S. A., Barcia, J., Guzmán, M., and Velasco, G. (2011) Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. Cell Death Differ. 18, 959-973
27. Marcellino, S., Attar, H., Lièvremont, D., Lett, M. C., Barbier, F., and Lagarde, F. (2008) Heat-treated Saccharomyces cerevisiae for antimony speciation and antimony(III) preconcentration in water samples. Anal. Chim. Acta 629, 73-83
28. Navarro, G., Ferré, S., Cordomi, A., Moreno, E., Mallol, J., Casadó, V., Cortés, A., Hoffmann, H., Ortiz, J., Canela, E. I., Lluís, C., Pardo, L., Franco, R., and Woods, A. S. (2010) Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers. J. Biol. Chem. 285, 27346-27359
29. Rios, C., Gomes, I., and Devi, L. A. (2006) Oαpioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br. J. Pharmacol. 148, 387-395
30. Ellis, J., Pediani, J. D., Canals, M., Milasta, S., and Milligan, G. (2006) Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and-independent coordinated alterations of receptor localization and function. J. Biol. Chem. 281, 38812-38824
31. Rozenfeld, R., Gupta, A., Gagnidze, K., Lim, M. P., Gomes, I., Lee-Ramos, D., Nieto, N., and Devi, L. A. (2011) AT1R-CB(1)R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J. 30, 2350-2363
32. Kargl, J., Balenga, N., Parzmair, G. P., Brown, A. J., Heinemann, A., and Waldhoer, M. (2012) The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J. Biol. Chem. 287, 44234-44248
33. Pertwee, R. G. (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 156, 397-411
34. Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K., Greasley, P. J., Ross, R. A., and Rogers, M. J. (2009) The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. U.S.A. 106, 16511-16516
35. Rempel, V., Volz, N., Gläser, F., Nieger, M., Bräse, S., and Müller, C. E. (2013) Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. J. Med. Chem. 56, 4798-4810
36. Moreira, F. A., and Wotjak, C. T. (2010) Cannabinoids and anxiety. Curr. Top. Behav. Neurosci. 2, 429-450
37. Sañudo-Peña, M. C., Romero, J., Seale, G. E., Fernandez-Ruiz, J. J., and Walker, J. M. (2000) Activational role of cannabinoids on movement. Eur. J. Pharmacol. 391, 269-274
38. Sulcova, E., Mechoulam, R., and Fride, E. (1998) Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 59, 347-352